In a report published Thursday, Sterne Agee analyst Greg T. Bolan initiated coverage on Cardinal Health CAH with a Neutral rating and $48.00 price target.
In the report, Sterne Agee noted, “With dominant market share of the independent pharmacy drug distribution channel, we believe CAH's profitability will benefit from an acceleration in brand-to-generic conversion in CY14/15. However, with EPS growth in CY14 that should be inferior to that of its peers, we do not believe CAH shares will outperform the peer group over the NTM. We initiate with a Neutral rating and $48 price target.”
Cardinal Health closed on Wednesday at $53.32.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in